AGN Argenica Therapeutics Limited
Healthcare · Biotechnology
· website
$0.15
52wk 0.09 – 0.77
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Argenica Therapeutics Limited
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$19.91M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.08
Dividend yield
—
Payout ratio
0.0%
Beta
0.76
EV / EBITDA
—
Price / Book
5.74
ROE
-117.8%
Operating margin
-623.9%
Net margin
0.0%
Total cash
$5.04M
Total debt
$0
Current ratio
2.96
Debt / Equity
—
Free cash flow
$-6.57M
Avg volume
358,168
Latest annual results
(FY ending 30 Jun 2025)
- Revenue—
- Gross profit—
- Operating income-$10.90M
- Net income-$7.17M
- Diluted EPS-0.06
- Free cash flow-$5.70M
- Net debt-$10.56M